BRAF and melanoma: Although the development of immunotherapeutics like ipilimumab or pembrolizumab and of drugs targeting mutated BRAF like vemurafenib or dabrafenib has improved treatment options and survival for melanoma patients [1, 2], the curative treatment of advanced melanoma still remains a challenging future goal [3].